Literature DB >> 31420290

New anticonvulsant candidates prevent P-glycoprotein (P-gp) overexpression in a pharmacoresistant seizure model in mice.

Andrea Verónica Enrique1, Mauricio Emiliano Di Ianni1, Sofía Goicoechea1, Alberto Lazarowski2, María Guadalupe Valle-Dorado3, Juan José López Costa4, Luisa Rocha3, Elena Girardi4, Alan Talevi5.   

Abstract

Despite the approval of a considerable number of last generation antiepileptic drugs (AEDs) (only in the last decade, six drugs have gained Food and Drug Administration approval), the global figures of seizure control have seemingly not improved, and available AED can still be regarded as symptomatic treatments. Fresh thinking in AEDs drug discovery, including the development of drugs with novel mechanisms of action, is required to achieve truly innovative antiepileptic medications. The transporter hypothesis proposes that inadequate penetration of AEDs across the blood-brain barrier, caused by increased expression of efflux transporters such as P-glycoprotein (P-gp), contributes to drug-resistant epilepsy. Neuroinflammation due to high levels of glutamate has been identified as one of the causes of P-gp upregulation, and several studies in animal models of epilepsy suggest that antiinflammatory drugs might prevent P-gp overexpression and, thus, avoid the development of refractory epilepsy. We have applied ligand-based in silico screening to select compounds that exert dual anticonvulsant and antiinflammatory effects. Five of the hits were tested in animal models of seizure, with protective effects. Later, two of them (sebacic acid (SA) and gamma-decanolactone) were submitted to the recently described MP23 model of drug-resistant seizures. All in all, SA displayed the best profile, showing activity in the maximal electroshock seizure (MES) and pentylenetetrazol (PTZ) seizure models, and reversing resistance to phenytoin (PHT) and decreasing the P-gp upregulation in the MP23 model. Furthermore, pretreatment with SA in the pilocarpine status epilepticus (SE) model resulted in decreased histamine release in comparison with nontreated animals. This is the first report of the use of the MP23 model to screen for novel anticonvulsant compounds that may avoid the development of P-gp-related drug resistance.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; Ketogenic diet; MP23 model; P-glycoprotein; Refractory epilepsy; Sebacic acid

Year:  2019        PMID: 31420290     DOI: 10.1016/j.yebeh.2019.106451

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

Review 1.  Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis.

Authors:  Mahin Khatami
Journal:  Clin Transl Med       Date:  2020-12

2.  Polysaccharides, Next Potential Agent for the Treatment of Epilepsy?

Authors:  Xuemin Xie; Youliang Wu; Haitao Xie; Haiyan Wang; Xiaojing Zhang; Jiabin Yu; Shaofang Zhu; Jing Zhao; Lisen Sui; Shaoping Li
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

3.  Impact of ABCB1 Polymorphisms on Lacosamide Serum Concentrations in Uygur Pediatric Patients With Epilepsy in China.

Authors:  Ting Zhao; Hong-Jian Li; Jie Feng; Hui-Lan Zhang; Wang Ting-Ting; Long Ma; Jing Yu; Wen-Bo Zhao; Li Sun; Lu-Hai Yu; Yan Sun
Journal:  Ther Drug Monit       Date:  2021-10-05       Impact factor: 3.118

Review 4.  Antiseizure medication discovery: Recent and future paradigm shifts.

Authors:  Alan Talevi
Journal:  Epilepsia Open       Date:  2022-02-07

Review 5.  Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

Authors:  Liliana Czornyj; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2021-10-29

Review 6.  A complex systems view on the current hypotheses of epilepsy pharmacoresistance.

Authors:  Gabriel Servilha-Menezes; Norberto Garcia-Cairasco
Journal:  Epilepsia Open       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.